In this episode, Dr Rachel Giles dives into clinical trial results presented at the ASCO Genitourinary Cancers Symposium 2021. Topics include:
- CheckMate 9ER: Superior clinical outcomes and quality of life with nivolumab plus cabozantinib in renal cell cancer
- EV-201: Enfortumab vedotin as treatment option for bladder cancer
- New therapeutic option for early metastatic testicular seminoma
- Reduced radiation exposure in testicular seminoma surveillance is possible
- Apalutamide treatment in prostate cancer
- EV-301: New therapy prolongs survival in urothelial carcinoma
Posted on
Table of Contents: ASCO GU 2021
Featured articles
Prostate Cancer
Lu177 as a promising new therapy for metastatic prostate cancer
Role of prostate cancer genomics is evolving
Apalutamide prolongs progression-free survival in prostate cancer
Dose-intensified radiation therapy fails to provide better outcomes in prostate cancer
Intrinsic tumour biology may be predictive of treatment response in prostate cancer
Final TITAN trial results favour use of apalutamide
Penile Cancer
Prognosis of penile cancer associated with HPV status
Renal Cancer
Superior clinical outcomes and QoL with nivolumab plus cabozantinib in RCC
Lenvatinib plus pembrolizumab prolongs survival in renal cell carcinoma
Inflammatory markers may guide treatment decisions in metastatic renal cell cancer
Clinical trial exclusion criteria may lead to lack of evidence in real-world patients: how do the excluded fare?
Axitinib offers hope for improving renal cell cancer surgical outcomes
Cabozantinib as possible new first-line therapy in translocation renal cell carcinoma
Predictors of oral anti-cancer agent utilisation in renal cell carcinoma
Denosumab plus pembrolizumab in advanced clear cell renal cell carcinoma
Testicular Cancer
New prediction model for brain metastasis in germ cell tumours
Reduction in radiation exposure is possible in testicular seminoma surveillance
New therapeutic option for early metastatic seminoma
Urothelial Cancer
Poorer outcomes in bladder cancer predicted by race/ethnicity and gender
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 3 results
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 2 results
New standard of care recommended for patients with upper tract urothelial cancer
Signature DNA alterations in subtypes of bladder cancer
ACE inhibitors associated with superior responses in bladder cancer
Better allocation of research dollars needed
Better prediction of favourable responses to immune checkpoint inhibitors in mUC
Genitourinary Oncology
Researchers call for an overhaul of licensing and funding of anti-cancer drugs
Exploring a new strategy for metastatic germ cell tumours
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com